Risk minimisation measures for medicines

AI Summary

This regulatory guidance document outlines the framework for Risk Minimisation Measures (RMMs) required by the UK Medicines and Healthcare products Regulatory Agency (MHRA). The core focus is on the obligations of Marketing Authorisation Holders (MAHs) to ensure the safe and effective distribution and consumption of medicinal products. According to the framework, MAHs must implement routine risk minimisation protocols as a standard condition of market access. These mandatory actions include establishing the legal status of the medicine, such as prescription-only restrictions, regulating pack sizes, and producing comprehensive documentation including the Summary of Product Characteristics (SmPC) and the Patient Information Leaflet (PIL). These measures are designed to inform healthcare professionals, patients, and caregivers about safety concerns post-market. While these routine measures are standard for all products, the guidance specifies that certain medicines may require additional, specialized risk minimisation strategies to address unique safety profiles. Although the provided text does not reference a specific company inspection or violation, it establishes the broad regulatory requirements that all pharmaceutical manufacturers must follow to maintain compliance with safety standards and protect public health. MAHs are expected to integrate these safety measures into their product lifecycle management to mitigate potential risks associated with medication use.